Lysophospholipids in Lung Inflammatory Diseases

14Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The lysophospholipids (LPLs) belong to a group of bioactive lipids that play pivotal roles in several physiological and pathological processes. LPLs are derivatives of phospholipids and consist of a single hydrophobic fatty acid chain, a hydrophilic head, and a phosphate group with or without a large molecule attached. Among the LPLs, lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are the simplest, and have been shown to be involved in lung inflammatory symptoms and diseases such as acute lung injury, asthma, and chronic obstructive pulmonary diseases. G protein–coupled receptors (GPCRs) mediate LPA and S1P signaling. In this chapter, we will discuss on the role of LPA, S1P, their metabolizing enzymes, inhibitors or agonists of their receptors, and their GPCR-mediated signaling in lung inflammatory symptoms and diseases, focusing specially on acute respiratory distress syndrome, asthma, and chronic obstructive pulmonary disease.

Cite

CITATION STYLE

APA

Zhao, J., & Zhao, Y. (2021). Lysophospholipids in Lung Inflammatory Diseases. In Advances in Experimental Medicine and Biology (Vol. 1303, pp. 373–391). Springer. https://doi.org/10.1007/978-3-030-63046-1_20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free